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Metal complex catalysis in living biological systems
Pijus K. Sasmal,a Craig N. Streub and Eric Meggers*ac
This feature article discusses synthetic metal complexes that are capable of catalyzing chemical
transformations in living organisms. Photodynamic therapy exemplifies what is probably the most
established artificial catalytic process exploited in medicine, namely the photosensitized catalytic
generation of cell-damaging singlet oxygen. Different redox catalysts have been designed over the last
two decades to target a variety of redox alterations in cancer and other diseases. For example,
pentaazamacrocyclic manganese(II) complexes catalyze the dismutation of superoxide to O2 and H2O2
in vivo and thus reduce oxidative stress in analogy to the native enzyme superoxide dismutase.
Recently, piano-stool ruthenium and iridium complexes were reported to influence cellular redox
homeostasis indirectly by catalytic glutathione oxidation and catalytic transfer hydrogenation using the
coenzyme NADH, respectively. Over the last few years, significant progress has been made towards the
application of non-biological reactions in living systems, ranging from the organoruthenium-catalyzed
cleavage of allylcarbamates and a gold-catalyzed intramolecular hydroarylation to palladium-catalyzed
Suzuki–Miyaura and Sonogashira cross-couplings within the cytoplasm or on the surface of living cells.
The design of bioorthogonal catalyst/substrate pairs, which can passively diffuse into cells, combines
the advantages of small molecules with catalysis and promises to provide exciting new tools for future
chemical biology studies.
Introduction
The last decade has witnessed the development of increasingly
powerful chemical tools for the modulation, sensing, and
imaging of biological processes in living systems.1 Today,
synthetic molecules based on diverse chemical scaffolds and
discovered through sophisticated strategies are capable of
highly selectively interfering with individual enzyme functions
or protein–protein interactions. At the same time, progress with
the design of bioorthogonal reactions permits the controlled
intracellular execution of synthetic chemistry without inter-
ference from the myriad of surrounding biological compo-
nents. One might wonder if there is any other untapped
chemistry imaginable that could serve as the next generation
of powerful chemical tools for modulating biology. We believe
this is indeed the case, namely the transition from mainly
exploiting stoichiometric events or reactions to applying cata-
lytic processes. Many attractive applications can be envisioned,
ranging from turning over protected, caged substrates multiple
times, catalytically labeling or deactivating target biomolecules,
to catalytically activating prodrugs at their cellular destination.
The advantage of signal amplification through catalytic
turnover has been successfully exploited already in the area of
enzyme-triggered bioimaging and nucleic-acid-based sensing.2,3
However, the design of bioorthogonal synthetic catalyst/substrate
pairs which can passively diffuse into cells for use as tools in
chemical biology studies  thus combining the advantages
of small molecules with catalysis  is a highly formidable
challenge that has only recently started to come to fruition.
We here review and discuss progress in this exciting area of
catalytic chemistry at the interface with biology and use cata-
lysis in living systems as our yardstick (Fig. 1).
Fig. 1 Overview of metal-complex-catalyzed reactions in living biological
systems. ROS = reactive oxygen species, RNS = reactive nitrogen species,
GSH = glutathione.
a Fachbereich Chemie, Philipps-Universität Marburg, Hans-Meerwein-Straße,
35043 Marburg, Germany. E-mail: meggers@chemie.uni-marburg.de
b Department of Chemistry and Biochemistry, St. Mary’s College of Maryland,
St. Mary’s City, MD 20686, USA
c Department of Chemical Biology, College of Chemistry and Chemical Engineering,
Xiamen University, Xiamen 361005, P. R. China
Received 29th October 2012,


















































View Journal  | View Issue
1582 Chem. Commun., 2013, 49, 1581--1587 This journal is c The Royal Society of Chemistry 2013
Redox catalysis
The concept of exploiting catalysis for the amplification of a
biological effect is actually not new and has been clinically
implemented with photodynamic therapy (PDT) for the treat-
ment of cancer and a few other diseases (e.g. skin lesions and
age-related macular degeneration).4 In PDT, nontoxic organic
or metal-containing photosensitizers are employed as catalysts
for the light-induced generation of highly reactive singlet
oxygen (1O2), which then initiates cell-damaging oxidation
reactions. Recently, a photosensitizer prodrug was reported
that becomes activated by a specific endogenous ribonucleic
acid.5 The reactivity of singlet oxygen has also been exploited
for the chromophore-assisted light inactivation of individual
proteins and nucleic acids in living cells.6,7
Over the last decade, increased efforts have been devoted
towards targeting redox alterations in cancer and other diseases.8
For example, tumors frequently exhibit high oxidative stress
with an increased production of reactive oxygen species (ROS).
The consequential increased vulnerability of cancer cells to
modulations of the ROS homeostasis has therefore been exploited
with oxidative stress promoting redox catalysts such as gadolinium
texaphyrins, anthracyclines, iron chelators, and nanoparticles,8,9
but also organometallic compounds such as the multifunc-
tional redox catalyst organotelluride LAB027 (1) (Fig. 2).10,11
In certain oxidative stress related diseases, such as reperfusion
injury (e.g. which occurs after stroke) and inflammatory pro-
cesses (e.g. arthritis), the production of the highly reactive
superoxide anion is enhanced, resulting in oxidative cell
damage. Pentaazamacrocyclic MnII([15]aneN5) complexes have
demonstrated high activity and biocompatibility as superoxide
dismutase (SOD) mimics with excellent potential for treating
a variety of diseases associated with oxidative stress.12 For
example, the manganese(II) complex M40403 (2) catalyzes the
dismutation of superoxide to O2 and H2O2 with a rate approaching
the native Mn SOD enzyme and, revealingly, the injection of M40403
into rat models of inflammation and ischemia-reperfusion
injury protected the animals against tissue damage.13 A recent
study demonstrated an additional protective effect of this class
of SOD mimics by completely scavenging nitric oxide and
peroxynitrite.14 Peroxynitrite is formed through the diffusion
controlled reaction of superoxide with nitric oxide and itself
constitutes a potent inducer of cell death.15 Metalloporphyrins
and derivatives with the metals manganese and iron, some of
which are currently developed for clinical applications, cata-
lytically decompose peroxynitrite and have been demonstrated
to attenuate the toxic effects of peroxynitrite in vitro and in vivo.
The cellular redox homeostasis can also be targeted in a
more indirect fashion. For example, glutathione (GSH) is a
major reductant in cells, inactivating reactive oxygen species
and serving as a cofactor for redox modulating enzymes. The
depletion of GSH could therefore affect the ability of cancer
cells to cope with oxidative damage. Intriguingly, Sadler and
co-workers have recently reported that ‘‘piano-stool’’ ruthenium
arene complexes such as [(Z6-biphenyl)Ru(2-(p-N,N-dimethyl-
aminophenylazo)pyridine)I]PF6 (3) are highly cytotoxic to
human ovarian and lung cancer cell lines despite their inert-
ness towards hydrolysis.16 The authors demonstrated that such
organoruthenium complexes are catalysts for the oxidation of
GSH to glutathione disulfide (GSSG) and this redox catalysis
might, at least in part, be responsible for the anticancer activity
of this class of catalytic drugs. The proposed catalytic cycle
involves ligand-centered reduction of the azo group to a hydra-
zine, initiated by a nucleophilic addition of GSH to the azo
group, followed by the oxidative regeneration of the azo group
with molecular oxygen. Interestingly, the same group recently
disclosed a family of ruthenium and iridium arene complexes
that are capable of catalyzing transfer hydrogenation using the
coenzyme NADH as a cofactor and they demonstrated that
iridium complex 4 affects the NAD+/NADH ratio within human
A2780 ovarian cancer cells, thus potentially interfering with the
function of NADH-dependent redox enzymes.17
Catalytic functional group conversions
The catalytic conversion of functional groups such as the
removal of protection groups is an attractive objective because
it permits the design of catalytically activatable prodrugs or
signal amplification with masked imaging probes. Our labora-
tory was the first to report an example of a protection group
which can be removed catalytically within a living biological
system.18,19 We found that the ruthenium(II) half-sandwich
complex [Cp*Ru(COD)Cl] (5), with Cp* = pentamethylcyclo-
pentadienyl and COD = 1,5-cyclooctadiene, is capable of cleaving
allylcarbamates (6) to their respective primary amines (7) in the
presence of water, air, and thiols (Scheme 1). Thiols, preferably
aromatic thiols, are actually required for the catalytic cleavage.
To evaluate the Ru-catalyzed allylcarbamate cleavage in more
relevant biological environments such as living mammalian cells,
we utilized the caged, non-fluorescent N,N-bis-allyloxycarbonyl-
protected rhodamine 110 (8) as a cellular probe, which can be
converted to green fluorescent rhodamine 110 (9) upon cleavage
of both allylcarbamate moieties (Fig. 3). Accordingly, HeLa cells
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washing with fresh medium in order to ensure that the caged
fluorophore was only present within the living cells. Fig. 3
demonstrates that subsequent addition of the ruthenium
complex 5 and thiophenol resulted in a rapid increase in
fluorescence as monitored by confocal fluorescence micro-
scopy. This fluorescence development was more pronounced
in the presence of thiophenol reaching a 10-fold increase
within a time period of 15 min within the cytoplasm of the
HeLa cells. We have recently extended this system by reporting
the ruthenium complex [Cp*Ru(Z6-pyrene)]PF6 (10) (Scheme 1)
as a photoactivatable catalyst for the cleavage of allylcarbamates
and demonstrated its utility in HeLa cells.20
In the quest for other biocompatible protection groups, our
laboratory recently envisioned the use of organic azides as
‘‘masked amines’’ since amines are important functional
groups in fluorophores and drugs, making possible a variety
of applications for employing organic azides as catalytically
activatable caging groups.21 Furthermore, organic azides are
absent from biological systems and thus fulfill an important
requirement of bioorthogonality which is a key feature of click
chemistry.1a,g In the course of screening a variety of metal
complexes, we found that [Fe(TPP)Cl], with TPP = 5,10,15,20-
tetraphenylporphine, smoothly catalyzes the reduction of
aromatic azides to their respective amines in the combined
presence of aliphatic thiols, protic solvents, and air. For example,
the reaction of p-chlorophenylazide (11, with R = Cl) with
5 equivalents of b-mercaptoethanol as the reducing agent and
1 mol% of [Fe(TPP)Cl] in CH2Cl2 : MeOH 95 : 5 under air at
30 1C, provided p-chloroaniline (12, with R = Cl) in 86% isolated
yield (Scheme 2).22 This reduction works similarly well for
electron-poor and electron-rich aromatic azides and was
demonstrated to proceed with very low catalyst loading of just
0.05 mol% [Fe(TPP)Cl]. To evaluate the iron porphyrin catalyzed
azide reduction under more biologically relevant conditions, we
used the bisazide 13 and monitored its [Fe(TPP)Cl]-catalyzed
conversion to the green fluorescent rhodamine 110 (9) under
varying reaction conditions (Fig. 4). As expected, the catalytic
reduction relies on the presence of thiols, which apparently
serve as the reducing agent, with aromatic thiols giving superior
results to aliphatic thiols, and benefiting from an additional
presence of the reducing agent ascorbate. Thus, the existing
reducing conditions within cellular cytosol should be ideally
suited for the [Fe(TPP)Cl]-catalyzed reduction of aromatic
azides. In fact, when we loaded cultured HeLa cells with the
bisazide 13 (incubation at 100 mM for 25 min followed by
Scheme 1 Thermal and photoactivated ruthenium catalyst (l Z 330 nm) for
the cleavage of allylcarbamates under bio-relevant conditions.
Fig. 3 Ruthenium-catalyzed uncaging of the bisallylcarbamate-protected rhodamine 110 (8) after uptake by HeLa cells. Shown are superimposed phase contrast and
fluorescence images. Cells were preincubated with 100 mM of 8 for 30 min, washed with PBS buffer, and then treated with 20 mM [Cp*Ru(COD)]Cl (5) and 500 mM
thiophenol. Shown images are taken immediately after this addition (a) and after 15 min (b). Analogous results were obtained with the catalyst 10 upon activation
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washing the cells with PBS buffer and the subsequent addition
of fresh medium), the addition of [Fe(TPP)Cl] to the medium
(10 mM) resulted in a rapid development of green fluorescence
as monitored by live cell imaging with a confocal fluorescence
microscope, with a 28-fold increase in fluorescence over a time
period of just 10 min. (Fig. 4). Thus, the mild and efficient
[Fe(TPP)Cl]-catalyzed reduction of aromatic azides to their
respective amines uses thiols as the reducing agent and toler-
ates water, air, and other biological components, rendering it a
rare example of a catalytic reaction that can be performed under
physiological conditions such as in living mammalian cells.
However, we found that in the nematode Caenorhabditis elegans
as well as the zebrafish (Danio rerio) the bisazide 13 is metabolised
quickly into rhodamine 110 without the need for [Fe(TPP)Cl], thus
revealing a limited bioorthogonality of aryl azides.22
Catalysis of carbon–carbon bond formations
The importance of the development and application of methods
for the formation of C–C bonds is manifested by the recently
awarded Nobel Prize for Pd-catalyzed cross-coupling reactions,
one of the most versatile tools for the generation of bonds
between carbon atoms. Whereas organic chemists are predomi-
nately focusing on developing methods under highly defined
reaction conditions and in organic solvents, the capability to
apply mild C–C bond formation methods at will within a living
biological system opens up exciting future opportunities in
chemical biology and medicinal chemistry, such as the
bioorthogonal tagging of biomolecules or the assembly of drugs
from two or more components at its final cellular destination.
Here we will highlight examples of metal-catalyzed C–C
bond formation reactions that have been tested in cellular
experiments.
A recent surge in homogeneous gold-catalyzed transforma-
tions has exploited gold ions as mild and carbophilic Lewis
acids for the activation of carbon–carbon p-bonds and in
particular alkynes.23 This ‘‘alkynophilicity’’ has been used to
design fluorescence sensors for the detection of gold(III) and
gold(I) ions in biological systems and even in living mammalian
cells.24 However, most systems are reported to rely on stoichio-
metric amounts of gold ions. In contrast, Kim, Kim, Yoon, and
co-workers recently revealed a turn-on fluorescent sensor for
gold(III) based on a catalytic intramolecular hydroarylation
resulting in formation of a fluorescent coumarin dye (14 - 15,
Scheme 3).25 The authors applied this sensor to the fluores-
cence microscopic detection of gold ions in fixed human
keratinocyte cells.
Palladium catalysis in living biological systems was first
reported for the hydrogenation of membrane lipids of cyano-
bacteria, plant, and mammalian cells.26 Li and Chen recently
reviewed newer developments regarding Pd-mediated chemistry
in biological systems.27 We will here highlight only Pd-catalyzed
C–C bond formations that have been performed in living bio-
logical systems. Most notably, Bradley and co-workers recently
reported palladium nanoparticles trapped within polystyrene
microspheres as heterogeneous Pd0-catalysts with the ability to
enter mammalian cells and catalyze an intracellular Suzuki–
Miyaura cross-coupling (Scheme 4).28,29 To this end, HeLa cells
were incubated with Pd-microspheres for 24 hours, followed by
intensive washing of the cells in order to eliminate any extra-
cellular palladium. Subsequently, the triflate 16 (20 mM) and
the boronic ester 17 (20 mM) were added to the medium and
Scheme 2 [Fe(TPP)]Cl-catalyzed reduction of aromatic azides to amines with
thiols as reducing agents.
Fig. 4 [Fe(TPP)Cl]-catalyzed reduction of bisazide 13 to green fluorescent
rhodamine 110 (9) within living HeLa cells. Shown are superimposed phase
contrast and confocal fluorescence images in which HeLa cells were preincubated
with 100 mM of bisazide 13 for 25 min, washed with PBS buffer, and subsequently
treated with 10 mM [Fe(TPP)Cl]. See ref. 22 for more details.
Scheme 3 Gold(III)-catalyzed cyclic hydroarylation reported by Kim, Kim, Yoon,
and co-workers.25 The formation of coumarin fluorescence was applied to verify
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incubated for 48 hours. Confocal fluorescence microscopy
revealed the development of mitochondria-localized fluores-
cence, which could be traced back to the anthofluorescein
dye 18 by extraction from cells, and confirmation of its identity
by HPLC and mass spectrometry. Interestingly, in control
experiments the authors found that the triflate 16 was remark-
ably robust so that the development of fluorescence from
hydrolyzed triflate 16 could be ruled out. Thus, from this study
it was concluded that intracellular Pd-nanoparticles catalyzed
the aryl–aryl coupling between the aryl triflate of 16 and the aryl
boronic ester moiety of 17. Opening of the lactone then
restored fluorescence by generation of a delocalized p-system
(18) and the lipophilic triphenylphosphonium moiety caused
the accumulation within mitochondria.
Davis and co-workers recently reported the Pd-catalyzed
labeling of the cell surface of Escherichia coli.30 For this, the
unnatural amino acid p-iodophenylalanine was incorporated
into the loop region of the channel protein OmpC via amber
stop codon suppression. The OmpC protein folds into a
b-barrel and assembles into a trimer within the bacterial
membrane and the incorporation of the p-iodophenylalanine
into the extracellular loop region (loop 5) at position 232 was
shown to be most effective. In a typical experiment, genetically
modified Escherichia coli cells harboring p-iodophenylalanine-
containing OmpC porin channels were treated with the boronic
acid 19 (1.6 mM) and the previously designed phosphine-free,
water-soluble PdII-catalyst 2031 (0.35 mM) for 1 h at 37 1C in
pH 8 buffer, affording blue fluorescent Escherichia coli cells by
covalent labeling of OmpC with a fluorophore (Scheme 5). The
Pd-catalyst 20 was shown to be effective at concentrations for
which no significant cell toxicity was observed under the
reported reaction conditions.
Using a related Pd-catalyst, Lin and co-workers recently reported
a copper-free Sonogashira cross-coupling in bacterial cells.32
Scheme 4 Intracellular Suzuki–Miyaura cross-coupling with a cell-penetrating Pd0-based heterogeneous catalyst by Bradley et al.28,29















































1586 Chem. Commun., 2013, 49, 1581--1587 This journal is c The Royal Society of Chemistry 2013
Genetically modified Escherichia coli, which overexpresses a
modified ubiquitin protein that metabolically incorporates
homopropargylglycine at the C-terminus, was used for this
study. Treatment of such genetically engineered cells with
iodofluorescein 21 (100 mM) and the phosphine-free, water
soluble PdII-complex 22 (1 mM) in the presence of 5 mM
sodium ascorbate in sodium phosphate buffer, followed by
growing at 37 1C for 4 hours, resulted in green fluorescent cells
(Scheme 6). Lysis of the cells and workup allowed the isolation
of fluorescent ubiquitin, which the authors traced back to a
Sonogashira cross-coupling between the terminal alkyne on the
ubiquitin and the iodofluorescein inside of the Escherichia coli
cells. However, this study relied on the use of an excess of Pd
catalyst and the authors explain this to be necessary as a result
of the nonspecific sequestration of the Pd complex by cellular
proteins. This effect highlights one of the major challenges
inherent in using Pd catalysis efficiently in biological systems:
the lability of coordinative bonds to Pd combined with the
affinity of Pd to highly abundant, soft thiol nucleophiles within
biological systems.
Summary and outlook
This review has outlined the state of the art of metal complex
catalysis in living biological systems, ranging from therapeuti-
cally relevant redox catalysts to the development of catalytic
functional group conversions and catalyzed C–C bond forma-
tions. Moving bioorthogonal chemistry from merely stoichio-
metric reactions to catalytic cycles offers exciting future
opportunities exploiting signal amplification. However, the
challenges are formidable due to the desired concomitant
characteristics of substrate-catalyst bioorthogonality and high
catalyst turnover numbers. The latter has not been reported for
any catalytic system operating in a living biological system but
we expect these numbers to be modest. It is our experience
from screening dozens of metal-based catalysts for their use in
biological systems that it is especially the combination of water,
air, and thiols that eventually deactivates the metal catalysts.
Reaching the efficiency of enzymes with small molecule cata-
lysts in complex biological systems – particularly considering a
toxicity-related desirable restriction to micromolar catalyst
concentrations  is therefore a considerable challenge and
we predict that the upcoming years will reveal not only solu-
tions to these challenges but subsequently also useful applica-
tions for such catalysts.
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